18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

Xiamen University

Status

Unknown

Conditions

18F-FDG

68Ga-FAPI

PET/CT

Lung Adenocarcinoma

Treatments

Diagnostic Test: 68Ga-FAPI PET/CT scan

Study type

Interventional

Funder types

Other

Identifiers

NCT04588064

KYZ2017-001

Details and patient eligibility

About

To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.

Full description

Participants with lung adenocarcinoma underwent contemporaneous 18F-FDG and 68Ga-FAPI PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 68Ga-FAPI PET/CT were calculated and compared to evaluate the diagnostic efficacy. In addition, the investigators further investigate the performance of 68Ga-FAPI PET/CT for differentiating invasive adenocarcinoma from adenocarcinoma in situ (pre-invasive lesion) or minimally invasive adenocarcinoma in participants with solitary ground-glass opacity nodules.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

(i) adult participants (aged 18 years or order);
(ii) participants with newly diagnosed lung adenocarcinoma;
(iii) participants who had scheduled both 18F-FDG and 68Ga-FAPI PET/CT scans;
(iv) participants who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

(i) participants with non-malignant lesions;
(ii) participants with pregnancy;
(iii) treatment has already started between the 2 PET scans;
(iv)the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.